Conjugated therapeutic proteins
Enhance your conjugated therapeutic protein development and manufacturing journey with our flexible and streamlined production capabilities.
Why develop conjugated therapeutic proteins?
Conjugated therapeutic proteins are being developed for a wide range of therapeutic applications, such as various cancers, infectious diseases and autoimmune disorders.
Conjugation can elevate the therapeutic properties of the protein by providing:
- Increased stability: Conjugation can help to stabilize therapeutic proteins, protecting them from degradation. This can extend a protein’s half-life in the body and allow it to exert its therapeutic effects for a longer period of time
- Improved potency: This can be achieved by increasing the protein’s affinity for its target, or by enhancing its ability to cross cell membranes
- Enhanced targeting: By attaching the protein to a ligand that specifically binds to a receptor on the surface of target cells, the specificity of conjugated therapeutics is increased
Understanding our conjugated therapeutic protein production capabilities
We can optimize upstream (fed-batch and perfusion) and downstream process development for enhanced productivity, quality and efficiency. Our development and manufacturing approach ensures streamlined production of efficacious and safe material that can help you reach the market quickly.
Why partner with Enzene for conjugated therapeutic proteins?
We are a global CDMO and biosimilar developer dedicated to impacting the global healthcare landscape by bringing trusted and affordable medicines to market, quickly.
We understand that each modality has unique requirements, and we are committed to providing you with the highest quality products and services. Our flexible development and manufacturing platforms allow us to quickly and efficiently produce modalities, regardless of their complexity or scale.
Our proprietary continuous bioprocess manufacturing platform, EnzeneX™ further enhances production, with accelerated rates and a significant reduction in the cost of producing complex modalities — from mAbs to complex proteins.
Related case studies
Latest resources
A modality for every need
Fueled by our continuous innovation and armed with our wide variety of modalities, we are dedicated to bringing your biologics innovations to life.